Logo-jnp
J Nephropathol. 2022;11(2): e12914.
doi: 10.34172/jnp.2022.12914
  Abstract View: 218
  PDF Download: 213

Original Article

The association of interleukin-6 (−174 G/C) polymorphism with risk of chronic kidney disease and erythropoietin hyporesponsiveness

Noha Alnair Abdelrhman 1, Elshazali Widaa Ali 2,1* ORCID logo

1 Faculty of Medical Laboratory Sciences, El Neelain University, Khartoum, Sudan
2 College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia
*Corresponding Author: Email: elshazaliwidaa@gmail.com

Abstract

Introduction: The plasma levels of the cytokine interleukin-6 (IL-6) have been reported to be associated with risk of chronic kidney disease (CKD) and erythropoietin (EPO) responsiveness. The G/C promoter polymorphism of IL-6 is associated with expression and levels of IL-6, so it may confer increased risk to CKD and modulate EPO responsiveness.

Objectives: This study aimed to examine the association of IL-6 G/C polymorphism with risk of CKD and EPO hyporesponsiveness.

Patients and Methods: A total of 40 haemodialysis patients on EPO therapy, and 30 age- and sexmatched apparently healthy volunteers as a control group were recruited for this study. Blood samples were collected from each participant and used for complete blood count (CBC) using automated haematology analyser and molecular analysis of IL-6 -174 G/C polymorphism using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).

Results: The results showed that IL-6 GG genotype is the most frequent in patients (82.5%) followed by GC genotype (17.5%), while all subjects of the control group were found to have GG genotype only. There was a statistically significant association between the polymorphism and end-stage CKD (P=0.02). Only 10% of the patients were found to achieve the target haemoglobin level. Although all of them had GG genotype, no association was found between the polymorphism and the achievement of target haemoglobin level (P=0.16).

Conclusion: IL-6 G/C polymorphism is significantly associated with CKD, but not with EPO responsiveness in haemodialysis patients.


Implication for health policy/practice/research/medical education:

In a case-control study on 40 hemodialysis patients and 30 apparently healthy volunteers as a control group we found that IL-10 -174 G/Cpolymorphism is significantly associated with the risk of end-stage renal disease. Although all patients achieved target hemoglobin levels, hadGG genotype, no statistically significant association was found between the polymorphism and erythropoietin responsiveness.

Please cite this paper as: Abdelrhman NA, Ali EW. The association of interleukin-6 (−174 G/C) polymorphism with risk of chronic kidneydisease and erythropoietin hyporesponsiveness. J Nephropathol. 2022;11(2):e12914. DOI: 10.34172/jnp.2022.12914.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 219

Your browser does not support the canvas element.


PDF Download: 213

Your browser does not support the canvas element.

Submitted: 31 Aug 2020
Accepted: 03 Nov 2020
ePublished: 19 Nov 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)